Binance links Bitcoin weakness to AI boom
Bitcoin’s recent decline may be driven more by investor enthusiasm for a handful of booming US equity sectors than by problems within the cryptocurrency market itself, according to Binance Research.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Bitcoin’s recent decline may be driven more by investor enthusiasm for a handful of booming US equity sectors than by problems within the cryptocurrency market itself, according to Binance Research.
Ethereum could be poised to outperform Bitcoin after Strategy’s first Bitcoin sale since 2022 highlighted advantages in Ethereum’s staking-based treasury model, according to Standard Chartered.
Global insurance broker and risk advisory firm WTW has acquired crypto insurance platform Redefind and launched a digital asset protection service aimed at helping clients recover stolen or lost cryptocurrency.
New data revealed that electrified vehicles captured 46% of all new car sales in Australia in May.
Georgia plans to install electricity meters across villages and settlements in the Mestia municipality as authorities intensify efforts to crack down on illegal cryptocurrency mining operations blamed for straining the region’s power grid.
Clean technology developer Hazer Group (ASX:HZR) has secured a patent from the Japanese Patent Office.
Senior Democratic lawmakers have called on the US Labor Department to abandon plans that would allow cryptocurrencies and other alternative assets to be included in Americans’ 401(k) retirement plans.
The Albanese Government has launched a review into Australia’s corporate and tax whistleblowing frameworks.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Vanderbilt Health announced that a Phase 2a clinical trial evaluating the investigational drug ifetroban successfully met its primary endpoint, demonstrating safety and tolerability in patients with high-risk solid tumors.
Vera Therapeutics (NASDAQ:VERA) has reached an agreement with the U.S. Food and Drug Administration to accelerate the regulatory timeline for its experimental kidney disease treatment, clearing the path for an earlier analysis of pivotal Phase 3 data.